Drug Trial Radar · NCT06431763
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
402
Actual
Start
Jun 21, 2024
Primary completion
Dec 1, 2025
Study completion Jan 2, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase IV, open-label, randomized study designed to evaluate the efficacy of Inclisiran vs. bempedoic acid (BPA) in 400 adult subjects (≥ 18 years) at very high and high risk for cardiovascular events as defined by the cardiovascular risk categories in the 2019 ESC/EAS guidelines for the management of dyslipidemias (Mach et al 2020) and elevated levels of LDL-C (≥ 70 mg/dL) despite being on a maximally tolerated high-intensity (HI) statin dose (+/- Ezetimibe). Currently, BPA is recommended ahead of injectables by German HTA body (GBA). A head-to-head trial is proposed to provide robust scientific data on the superiority of Inclisiran vs. BPA and to support the early use of Inclisiran.
Conditions
- Hypercholesterolemia
Interventions
Inclisiran sodiumDrug
300 mg s.c. administered at day 1 and day 90
BPADrug
180 mg daily per oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in LDL-C levelsTime frame: Baseline, Day 150
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Bad Homburg, Germany
Novartis Investigative Site
Bad Krozingen, Germany
Novartis Investigative Site
Bad Oeynhausen, Germany
Novartis Investigative Site
Bamberg, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Bremen, Germany
Novartis Investigative Site
Dessau, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Erfurt, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Falkensee, Germany
Novartis Investigative Site
Gladbeck, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hoyerswerda, Germany
Novartis Investigative Site
Kassel, Germany
Novartis Investigative Site
Kiel, Germany
Novartis Investigative Site
Ludwigshafen, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Markkleeberg, Germany
Novartis Investigative Site
Meissen, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Papenburg, Germany
Novartis Investigative Site
Pirna, Germany
Novartis Investigative Site
Potsdam, Germany
Novartis Investigative Site
Rüdersdorf, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Völklingen, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Stuttgart, Baden-Wurttemberg, Germany
Novartis Investigative Site
Lichtenfels, Bavaria, Germany
Novartis Investigative Site
Muehldorf Am Inn, Bavaria, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.